Department of Analytical Sciences, Abbott Vascular, Inc., Santa Clara, CA 95054-2807, USA.
J Pharm Biomed Anal. 2012 Nov;70:94-100. doi: 10.1016/j.jpba.2012.05.038. Epub 2012 Jun 4.
High-throughput 96-well solid phase extraction (SPE) plate with C-18 reversed phase sorbent followed by UV-visible (UV-Vis) microplate reader was applied to the analysis of hydrophobic drugs in surfactant-containing dissolution media, which are often used to evaluate the in-vitro drug release of drug eluting stents (DES). Everolimus and dissolution medium containing Triton X-405 were selected as representatives, and the appropriate SPE conditions (adsorption, washing and elution) were investigated to obtain a practical and reliable sample clean-up. It was shown that the developed SPE procedure was capable of removing interfering components (Triton X-405 and its impurities), allowing for an accurate automated spectrophotometric analysis to be performed. The proposed UV-Vis spectrophotometric method yielded equivalent results compared to a classical LC analysis method. Linear regression analysis indicated that both methods have the ability to obtain test results that are directly proportional to the concentration of analyte in the sample within the selected range of 1.0-10 μg/ml for everolimus, with a coefficient of correlation (r(2)) value of >0.998 and standard deviation of the residuals (Syx) of <2%. The individual recoveries of everolimus ranged from 97 to 104% for the UV-Vis spectrophotometric method and from 98 to 102 for the HPLC method, respectively. The 95% CI of the mean recovery for the UV-Vis spectrophotometric method was 99-102% and for the HPLC method was 99-101%. No statistical difference was found between the mean recoveries of the methods (p=0.42). Hence the methods are free from interference due to Triton and other chemicals present in the dissolution medium. The variation in the amount of everolimus estimated by UV-Vis spectrophotometric and HPLC methods was ≤3.5%, and the drug release profiles obtained by both methods were found to be equivalent by evaluation with two-one-sided t-test (two-tailed, p=0.62; mean of differences, 0.17; 95% CI, 0.62-0.96) and similarity factor f2 (f2 value, 87). The excellent conformity of the results makes UV-Vis spectrophotometer an ideal tool for analyzing the drugs in the media containing surfactants, after SPE. The 96-well SPE plates in combination with UV-Vis microplate reader provide a high throughput method for the determination of in-vitro drug release profile of DES. Switching from HPLC to UV-Vis spectrophotometer microplate reader assay reduces the solvent consumption and labor required for the sample analyses. This directly impacts the profitability of the laboratory.
采用高通量 96 孔固相萃取(SPE)板,使用 C-18 反相吸附剂,结合紫外-可见(UV-Vis)微板读数器,用于分析含有表面活性剂的溶解介质中的疏水性药物,这些药物通常用于评估药物洗脱支架(DES)的体外药物释放。以依维莫司和含有 Triton X-405 的溶解介质为例,研究了适当的 SPE 条件(吸附、洗涤和洗脱),以获得实用可靠的样品净化方法。结果表明,开发的 SPE 程序能够去除干扰成分(Triton X-405 及其杂质),从而能够进行准确的自动分光光度分析。与经典的 LC 分析方法相比,所提出的 UV-Vis 分光光度法可得到等效的结果。线性回归分析表明,两种方法都能够在 1.0-10μg/ml 的选定范围内获得与样品中分析物浓度直接成正比的测试结果,相关系数(r(2))值大于 0.998,残差标准差(Syx)小于 2%。依维莫司的 UV-Vis 分光光度法的个体回收率范围为 97-104%,HPLC 法的回收率范围为 98-102%。UV-Vis 分光光度法的平均回收率的 95%置信区间为 99-102%,HPLC 法的平均回收率的 95%置信区间为 99-101%。两种方法的平均回收率无统计学差异(p=0.42)。因此,这些方法不受 Triton 和溶解介质中其他化学物质的干扰。UV-Vis 分光光度法和 HPLC 法估计的依维莫司量的变化均≤3.5%,通过双单侧 t 检验(双侧,p=0.62;差值平均值,0.17;95%置信区间,0.62-0.96)和相似因子 f2(f2 值,87)对两种方法的药物释放曲线进行评估,发现结果等效。结果的极好一致性使得 UV-Vis 分光光度计成为在含有表面活性剂的介质中分析药物的理想工具,SPE 之后。96 孔 SPE 板与 UV-Vis 微孔板读数器结合,为 DES 的体外药物释放曲线的测定提供了高通量方法。从 HPLC 切换到 UV-Vis 分光光度计微孔板读数器测定,可减少溶剂消耗和样品分析所需的劳动力。这直接影响实验室的盈利能力。